PMID- 34111994
OWN - NLM
STAT- MEDLINE
DCOM- 20230622
LR  - 20230622
IS  - 1477-092X (Electronic)
IS  - 1078-1552 (Linking)
VI  - 28
IP  - 5
DP  - 2022 Jul
TI  - Real-world evidence for carfilzomib dosing intensity on overall survival and 
      treatment progression in multiple myeloma patients.
PG  - 1130-1139
LID - 10.1177/10781552211015283 [doi]
AB  - INTRODUCTION: Carfilzomib dosing as a single agent or in combination with 
      dexamethasone (Kd) has evolved from the initial 27 mg/m(2) twice-weekly (legacy 
      dose), to more recently approved doses of 56 mg/m(2) twice-weekly and 70 mg/m(2) 
      once-weekly (optimized doses). The objective of this study was to evaluate the 
      overall survival (OS), and time to next treatment (TTNT) among multiple myeloma 
      patients treated with Kd optimized vs legacy doses. METHODS: A retrospective 
      analysis of patients receiving Kd between 01/01/2013-07/31/2017 was conducted 
      using IQVIA's oncology electronic medical records database. Kd dose was estimated 
      based on body surface area. OS was measured from the Kd-initiation date until 
      death. TTNT was defined as the time from Kd-initiation until the start of 
      subsequent treatment. Kaplan-Meier analysis and Cox models were used to evaluate 
      OS and TTNT. RESULTS: Of the 1,469 patients evaluated, 129 (8.8%) received 
      optimized dose and 1,340 (91.2%) received legacy dose. Risk of mortality was 64% 
      lower for patients receiving the optimized doses (HR: 0.36, 95% CI: 0.178-0.745). 
      Patients receiving the optimized doses had significantly longer TTNT compared to 
      patients receiving the legacy dose (median TTNT: 17.5 months [95% CI: 14.8-NE] 
      and 13.2 months, [95% CI: 12.4-14.4], respectively; p = 0.023), and 33% lower 
      risk of progressing to the subsequent treatment (HR: 0.67, 95% CI: 0.48-0.93). 
      CONCLUSIONS: Patient outcomes could be improved if eligible MM patients are 
      treated with the optimized, recently approved Kd doses (56 mg/m(2) twice-weekly 
      and 70 mg/m(2) once-weekly).
FAU - Raje, Noopur
AU  - Raje N
AD  - Massachusetts General Hospital, Hematology/Oncology, Boston, MA, USA.
FAU - Medhekar, Rohan
AU  - Medhekar R
AD  - Amgen, Inc., Global Health Economics, Thousand Oaks, CA, USA.
FAU - Panjabi, Sumeet
AU  - Panjabi S
AD  - Amgen, Inc., Global Health Economics, Thousand Oaks, CA, USA.
FAU - Hines, Dionne M
AU  - Hines DM
AD  - IQVIA, Inc., Real World Evidence, One IMS Drive, Plymouth Meeting, PA, USA.
FAU - Wang, Xin
AU  - Wang X
AUID- ORCID: 0000-0002-9304-2167
AD  - IQVIA, Inc., Real World Evidence, One IMS Drive, Plymouth Meeting, PA, USA.
FAU - Iskander, Karim
AU  - Iskander K
AD  - Amgen, Inc., Global Health Economics, Thousand Oaks, CA, USA.
FAU - Welliver, Tim
AU  - Welliver T
AD  - Amgen, Inc., Global Health Economics, Thousand Oaks, CA, USA.
FAU - Wade, Rolin L
AU  - Wade RL
AD  - IQVIA, Inc., Real World Evidence, One IMS Drive, Plymouth Meeting, PA, USA.
FAU - Ailawadhi, Sikander
AU  - Ailawadhi S
AD  - Division of Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
LA  - eng
PT  - Journal Article
DEP - 20210610
PL  - England
TA  - J Oncol Pharm Pract
JT  - Journal of oncology pharmacy practice : official publication of the International 
      Society of Oncology Pharmacy Practitioners
JID - 9511372
RN  - 72X6E3J5AR (carfilzomib)
RN  - 0 (Oligopeptides)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Humans
MH  - *Multiple Myeloma/drug therapy
MH  - Retrospective Studies
MH  - Oligopeptides/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Dexamethasone
OTO - NOTNLM
OT  - Multiple myeloma
OT  - carfilzomib
OT  - survival
OT  - treatment duration
EDAT- 2021/06/12 06:00
MHDA- 2023/06/22 06:42
CRDT- 2021/06/11 05:32
PHST- 2023/06/22 06:42 [medline]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/06/11 05:32 [entrez]
AID - 10.1177/10781552211015283 [doi]
PST - ppublish
SO  - J Oncol Pharm Pract. 2022 Jul;28(5):1130-1139. doi: 10.1177/10781552211015283. 
      Epub 2021 Jun 10.